 |
|
Tacrolimus and Pimecrolimus for Atopic Dermatitis
Where Do They Fit In?
Michael Bigby, MD
Arch Dermatol. 2006;142:1203-1205.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Commentary on: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC
BMJ. 2005;330:516; doi:10.1136/bmj.38376.439653.D3
Question: For adults and children with atopic dermatitis, which are more effective and better tolerated in reducing the signs and symptoms of atopic dermatitis: topical pimecrolimus, tacrolimus, corticosteroids, or vehicle?
Design: Systematic review and meta-analysis.
Data Sources: Electronic searches of the Cochrane Library database, MEDLINE, and EMBASE.
Study Selection: Randomized controlled trials of topical pimecrolimus or tacrolimus reporting efficacy outcomes or tolerability.
Outcomes: Efficacy: investigators' global assessment of response; patients' global assessment of response; percentages of patients with flares of atopic dermatitis; and improvements in quality of life. Tolerability: overall rates of withdrawal; withdrawal owing to adverse events; and percentages of patients with burning of the skin and with skin infections.
. . . [Full Text of this Article] Comment
AUTHOR INFORMATION
Department of Dermatology, Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, Mass
RELATED ARTICLE
What Is Meant by a "Flare" in Atopic Dermatitis?: A Systematic Review and Proposal
Sinéad M. Langan, Kim S. Thomas, and Hywel C. Williams
Arch Dermatol. 2006;142(9):1190-1196.
ABSTRACT
| FULL TEXT
|
